BioSpace News Archive

Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the third quarter ended September 30, 2020 and provided a corporate update.

Onconova Therapeutics, Inc. (NASDAQ: ONTX), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that the Company intends to release its third quarter financial results on Thursday, November 12, 2020 after market close. Management plans to host a conference call and live webcast at 4:30 p.m.

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today reported financial results for the third quarter ended September 30, 2020.

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced the issuance of a $10.2 million unsecured promissory note (the “Note”) to an accredited investor for $10.0 million cash proceeds,

Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced that Scott Shively, Chief Executive Officer at Neumentum, will host one-on-one investor meetings during the Jefferies Virtual London Healthcare Conference being held November 17 – November 19, 2020.

Rezolute, Inc., a clinical stage biopharmaceutical company dedicated to advancing therapies for rare, metabolic and life-threatening diseases, announced that the Company’s common shares have been approved for listing on the Nasdaq Capital Market.

Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today the commercial launch of a small portable microplate reader for use with the company’s immunoassays and, ultimately, molecular diagnostics, providing new opportunities in point-of-care medicine.

IBEX Technologies Inc. reported its financial results for the fiscal year ended July 31, 2020.

Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), today announced that preclinical data from its Gamma Delta T Cell Engager, GADLEN™, platform has been accepted for poster presentation at the Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting,

NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that data from its Phase 1 study of NGM621, a potent anti-complement C3 antibody, will be featured in a poster presentation at the American Academy of Ophthalmology (AAO) 2020 Virtual.